General Instructions

Word Count: All abstract categories have a 300 count word limit.

Original Research:
Abstract Deadline: February 10, 2020, Midnight (23:59:59) PDT

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

• Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
• Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions. For ACCP's specific evaluation criteria, click here.
• Descriptions of planned research efforts or preliminary data will not be accepted.
• To be eligible for Best Poster, Student Best Poster, or Resident/Fellow Best Poster the abstract must fit and be submitted in this category. For specific eligibility criteria, click here.

Original research findings presented elsewhere and/or published only as an abstract, but important to clinical pharmacy, are encouraged as “Encore” presentations.

1. Abstracts submitted as Encore Original Research presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but they must be an author on the original abstract. Insert the original abstract text in the Abstract Text section of the submission process. (Note: ACCP-required headers and 300 maximum word count do not apply to Encore abstracts.)
2. The same abstract may not be presented at more than one national ACCP event.
3. The full abstract will be published in the Meeting App, only.
4. Only the abstract title, authors, and original citation will be published in JACCP.
5. Encore Presentations will not be eligible for the Best Poster Awards.
6. Submit Encore abstracts as Original Research and select "encore" when prompted, providing the original citation, and a copy of the original abstract.

A previously presented abstract may form the basis for a new (not “encore”) abstract to be submitted for consideration in the Original Research category if the previously presented abstract:

1. was a descriptive report of planned research only,
2. described preliminary results only and complete results are now available,
3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
4. was presented at an ACCP Chapter or PRN event, or
5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.

 

Clinical Pharmacy Forum: 
Abstract Deadline: February 10, 2020, Midnight (23:59:59) PDT

Abstracts must describe the delivery of, justification or documentation for, and impact/significance of innovative clinical pharmacy services which have been implemented. Descriptions of planned services or programs will not be accepted.

Abstracts that address comprehensive medication management (CMM) implementation (see www.accp.com/cmm), components of the ACCP Standards of Practice for Clinical Pharmacists (see www.accp.com/standards) and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component.

• Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
• Descriptions of planned services or programs will not be accepted.
• Abstracts will be evaluated based on originality of the service or program, adequacy of justification/documentation, adaptability to other settings, and significance to clinical pharmacy. For ACCP’s specific evaluation criteria, click here.
• Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).

 

Research-in-Progress: 
Abstract Deadline: March 2, 2020, Midnight (23:59:59) PDT

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

• Research-In-Progress abstracts may be submitted by any attendee (faculty/practitioner, resident, fellow, or student).
• In-Progress abstracts will be published in the Meeting App, only. 

Selection Notification:  Authors will be notified by e-mail of acceptance of their papers by Monday, March 16, 2020

Late-Breaking Original Research: Abstract Deadline: February 27, 2019, 11:59PM PDT

Word Count: All abstract categories have a 300 count word limit.

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

• Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
• Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions.
• Descriptions of planned research efforts or preliminary data will not be accepted.
• A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Late-Breaking Original Research category if the previous abstract:
  1. was a descriptive report of planned research only,
  2. described preliminary results only and complete results are now available,
  3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
  4. was presented at an ACCP Chapter or PRN event, or
  5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.